{
  "abstract": "Background Thoracoscopic talc pleurodesis remains a mainstay in the management of malignant pleural effusions (MPE). Integrating same site indwelling pleural catheter (IPC) insertion during thoracoscopy has been shown in recent studies to facilitate early discharge, improve pleurodesis success, and support outpatient care. However, real-world evidence on the safety and feasibility of this single-port combined approach remains limited.Methods This was a retrospective single-centre study of all consecutive patients who underwent single-port thoracoscopic talc pleurodesis with same-site IPC insertion between January 2019 and December 2024. Patients were followed for a maximum of 6 months. Data were collected on demographics, known malignancy at the time of the procedure, IPC duration (days), pleurodesis success (defined as IPC removal without recurrence of effusion), and procedure-related complications.Results A total of 194 patients were included (67.0% male; mean age 69 ± 11.5 years). Thirty-seven patients (19.1%) had a known malignancy at the time of thoracoscopy. IPCs remained in situ for more than 182 days in 11 patients (5.7%), and 18 patients (9.3%) died within 6 months with the IPC in place. Among those with IPC duration ≤182 days, the mean duration was 34.4 ± 34.8 days, with a median of 20 days (IQR 14–47).Although minor surgical emphysema involving the IPC port site or ipsilateral chest wall was common, significant surgical emphysema, defined as extension to at least the neck and subpectoralis major region was observed in 1 patient (0.5%). This patient required hospitalisation the following day for symptom management.IPC-related complications occurred in 10 patients (5.2%). Severe pain requiring early IPC removal was noted in 4 patients (2.1%). Infection was seen in 4 patients (2.1%): 3 (1.5%) had localised infections managed with a short course of antibiotics, while 1 (0.5%) developed malignant empyema necessitans. Leakage and catheter dislodgement were each observed in 1 patient (0.5%). Early IPC removal due to pain did not compromise pleurodesis success.Abstract P221 Table 1Summary table of key results Parameter Value Total patients194Gender distribution130 Male (67.0%), 64 Female (33.0%)Mean age ± SD69 ± 11.5 yearsKnown malignancy at procedure37 (19.1%)IPCs in situ >182 days11 (5.7%)Deaths with IPC in situ18 (9.3%)Mean IPC duration (≤182 days)34.4 ± 34.8 daysMedian IPC duration (≤182 days)20 days (IQR: 14–47)Significant surgical emphysema1 (0.5 %)IPC-related complications10 total (5.2%) — Severe Pain: 4 (40.0%), Infection: 4 (40.0%), Leakage: 1 (10.0%), Dislodged: 1 (10.0%)Conclusion Single-port thoracoscopic pleurodesis with same-site IPC insertion is a feasible and generally safe option for managing MPE and unexplained exudative effusions. The technique offers high pleurodesis success with manageable complications, supporting its use in routine clinical practice.",
  "authors": [
    {
      "affiliations": [
        "Kettering General Hospital NHS Foundation Trust, Kettering, UK"
      ],
      "name": "Y Rahim"
    },
    {
      "affiliations": [
        "Kettering General Hospital NHS Foundation Trust, Kettering, UK"
      ],
      "name": "S Khan"
    },
    {
      "affiliations": [
        "Kettering General Hospital NHS Foundation Trust, Kettering, UK"
      ],
      "name": "M Naeem"
    },
    {
      "affiliations": [
        "Kettering General Hospital NHS Foundation Trust, Kettering, UK"
      ],
      "name": "G Tsaknis"
    },
    {
      "affiliations": [
        "Kettering General Hospital NHS Foundation Trust, Kettering, UK"
      ],
      "name": "RV Reddy"
    }
  ],
  "title": "P221 Feasibility and safety of single-port thoracoscopic pleurodesis with same-site indwelling pleural catheter insertion for management of malignant and unexplained exudative pleural effusion",
  "uid": "60b5f77e-29cb-522a-a85d-57fac8dcc723"
}